Critical review of biomarkers for the early detection and surveillance of bladder cancer

Journal of Men's Health

Volumn 6, Issue 4, 2009, Pages 368-382

  Chade, Daher C ^a   Shariat, Shahrokh F ^a   Godoy, Guilherme ^a   Meryn, Siegfried ^b   Dalbagni, Guido ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarkers; Bladder neoplasms; Cystoscopy; Detection; Diagnosis; Prediction; Urothelial carcinoma

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; CYTOKERATIN 20; FAS ANTIGEN; HYALURONIC ACID; HYALURONIDASE; LEWIS X ANTIGEN; NUCLEAR MATRIX PROTEIN 22; SURVIVIN; TELOMERASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CARCINOGENESIS; CYSTOSCOPY; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; MICROSATELLITE MARKER; PRIORITY JOURNAL; RATING SCALE; REVIEW;

EID: 72149109801     PISSN: 18756867     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jomh.2009.07.004     Document Type: Review

References (136)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 2 (2008) 71-96
2. Shariat S.F., Karakiewicz P.I., Palapattu G.S., Lotan Y., Rogers C.G., Amiel G.E., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium. J Urol 176 6 (2006) 2414-2422
3. Stein J.P., Lieskovsky G., Cote R., Groshen S., Feng A.C., Boyd S., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 3 (2001) 666-675
4. Madersbacher S., Hochreiter W., Burkhard F., Thalmann G.N., Danuser H., Markwalder R., et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 21 4 (2003) 690-696
5. Prout Jr. G.R., Barton B.A., Griffin P.P., Friedell G.H., and The National Bladder Cancer Group. Treated history of noninvasive grade 1 transitional cell carcinoma. J Urol 148 5 (1992) 1413-1419
6. Pagano F., Bassi P., Galetti T.P., Meneghini A., Milani C., Artibani W., et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 145 1 (1991) 45-50
7. van der Poel H.G., and Debruyne F.M. Can biological markers replace cystoscopy? An update. Curr Opin Urol 11 5 (2001) 503-509
8. Herr H.W. The natural history of a T1 bladder cancer: life-long tumour diathesis. BJU Int 84 9 (1999) 1102-1103
9. Lotan Y., and Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61 1 (2003) 109-118 discussion 118
10. Karakiewicz P.I., Benayoun S., Zippe C., Ludecke G., Boman H., Sanchez-Carbayo M., et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 97 5 (2006) 997-1001
11. Lokeshwar V., and Soloway M. Current bladder tumor tests: does their projected utility fulfill clinical necessity?. J Urol 165 (2001) 1067-1077
12. Svatek R.S., Sagalowsky A.I., and Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol 24 4 (2006) 338-343
13. Lotan Y., Svatek R.S., and Sagalowsky A.I. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. Cancer 107 5 (2006) 982-990
14. Johnston B., Morales A., Emerson L., and Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 158 (1997) 2098-2101
15. Kinders R., Jones T., Root R., Bruce C., Murchison H., Corey M., et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 4 10 (1998) 2511-2520
16. Wiener H.G., Mian C., Haitel A., Pycha A., Schatzl G., and Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?. J Urol 159 6 (1998) 1876-1880
17. Takashi M., Schenck U., Kissel K., Leyh H., and Treiber U. Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients. Int Urol Nephrol 31 2 (1999) 189-196
18. Sharma S., Zippe C.D., Pandrangi L., Nelson D., and Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 162 1 (1999) 53-57
19. Gutierrez Banos J.L., Martin Garcia B., Hernandez Rodriguez R., Portillo Martin J.A., Correas Gomez M.A., del Valle Schaan J.I., et al. Utilidad del BTA Stat Test (Bard) en el diagnóstico del cáncer vesical. Resultados preliminares y comparación con citología y cistoscopia. Arch Esp Urol 51 8 (1998) 778-782
20. Landman J., Chang Y., Kavaler E., Droller M.J., and Liu B.C. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 52 3 (1998) 398-402
21. Leyh H., and Mazeman E. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. Eur Urol 32 (1997) 425-428
22. Leyh H., Marberger M., Conort P., Sternberg C., Pansadoro V., Pagano F., et al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 35 1 (1999) 52-56
23. Nasuti J.F., Gomella L.G., Ismial M., and Bibbo M. Utility of the BTA stat test kit for bladder cancer screening. Diagn Cytopathol 21 1 (1999) 27-29
24. Oge O., Kozaci D., and Gemalmaz H. The BTA stat test is nonspecific for hematuria: an experimental hematuria model. J Urol 167 3 (2002) 1318-1319 discussion 1319-20
25. Raitanen M.P. The role of BTA stat test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 26 1 (2008) 45-50
26. Malkowicz S.B. The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin of North Am 27 1 (2000) 63-73
27. Thomas L., Leyh H., Marberger M., Bombardieri E., Bassi P., Pagano F., et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 45 4 (1999) 472-477
28. Mahnert B., Tauber S., Kriegmair M., Schmitt U.M., Hasholzner U., Reiter W., et al. BTA-TRAK - a useful diagnostic tool in urinary bladder cancer?. Anticancer Res 19 4A (1999) 2615-2619
29. Irani J., Desgrandchamps F., Millet C., Toubert M.E., Bon D., Aubert J., et al. BTA stat and BTA TRAK: a comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 35 2 (1999) 89-92
30. Heicappell R., Wettig I.C., Schostak M., Muller M., Steiner U., Sauter T., et al. Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. Eur Urol 35 1 (1999) 81-87
31. Ellis W.J., Blumenstein B.A., Ishak L.M., Enfield D.L., and The Multi Center Study Group. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology 50 6 (1997) 882-887
32. Abbate I., D'Introno A., Cardo G., Marano A., Addabbo L., Musci M., et al. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer. Anticancer Res 18 5B (1998) 3803-3805
33. Babjuk M., Soukup V., Pesl M., Kostirova M., Drncova E., Smolova H., et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 71 4 (2008) 718-722
34. Tsui K.H., Chen S.M., Wang T.M., Juang H.H., Chen C.L., Sun G.H., et al. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China. Asian J Androl 9 5 (2007) 711-715
35. Fradet Y., and Lockhart C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol 4 (1997) 400
36. Greene K.L., Berry A., and Konety B.R. Diagnostic utility of the ImmunoCyt/uCyt+ test in bladder cancer. Rev Urol 8 4 (2006) 190-197
37. Olsson H., and Zackrisson B. ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol 35 (2001) 280-282
38. Mian C., Pycha A., Wiener H., Haitel A., Lodde M., and Marberger M. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 161 5 (1999) 1486-1489
39. Vriesema J.L., Atsma F., Kiemeney L.A., Peelen W.P., Witjes J.A., and Schalken J.A. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 58 3 (2001) 367-371
40. Mian C., Lodde M., Comploj E., Negri G., Egarter-Vigl E., Lusuardi L., et al. Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma. Cytopathology 14 6 (2003) 338-342
41. Pfister C., Chautard D., Devonec M., Perrin P., Chopin D., Rischmann P., et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 169 3 (2003) 921-924
42. Sullivan P.S., Nooraie F., Sanchez H., Hirschowitz S., Levin M., Rao P.N., et al. Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study. Cancer Cytopathol 117 3 (2009) 167-173
43. Gordon J.N., Shu W.P., Schlussel R.N., Droller M.J., and Liu B.C.S. Altered extracellular matrices influence cellular processes and nuclear matrix organisations of overlying human bladder urothelial cells. Cancer Res 53 (1993) 4971-4977
44. Berezney R., and Coffey D.S. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 60 4 (1974) 1410-1417
45. Pardoll D.M., Vogelstein B., and Coffey D.S. A fixed site of DNA replication in eukaryotic cells. Cell 19 (1980) 527-536
46. Compton D.A., and Cleveland D.W. NuMA is required for the proper completion of mitosis. J Cell Biol 120 (1993) 947-957
47. Shelfo S.W., and Soloway M.S. The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol 15 (1997) 107-111
48. Hughes J.H., Katz R.L., Rodriguez-Villanueva J., Kidd L., Dinney C., Grossman H.B., et al. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol 20 5 (1999) 285-290
49. Miyanaga N., Akaza H., Tsukamoto T., Ishikawa S., Noguchi R., Ohtani M., et al. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int J Urol 6 4 (1999) 173-177
50. Stampfer D., Carpinito G., Rodriguez-Villanueva J., Willsey L., Dinney C., Grossman H., et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 159 (1998) 394-398
51. Soloway M.S., Briggman J.V., Carpinito G.A., Chodak G.W., Church P.A., Lamm D.L., et al. Use of new tumor marker, urinary NMP22, in detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156 2 Pt 1 (1996) 363-367
52. Ramakumar S., Bhuiyan J., Besse J.A., Roberts S.G., Wollan P.C., Blute M.L., et al. Comparison of screening methods in the detection of bladder cancer. J Urol 161 2 (1999) 388-394
53. Ponsky L.E., Sharma S., Pandrangi L., Kedia S., Nelson D., Agarwal A., et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol 166 (2001) 75-78
54. Mansoor I., Calam R.R., and Al-Khafaji B. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma. Anal Quant Cytol Histol 30 1 (2008) 25-32
55. Shariat S.F., Marberger M.J., Lotan Y., Sanchez-Carbayo M., Zippe C., Ludecke G., et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 176 3 (2006) 919-926
56. Shariat S.F., Casella R., Wians Jr. F.H., Ashfaq R., Balko J., Sulser T., et al. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 45 3 (2004) 304-313 author reply 313
57. Shariat S.F., Zippe C., Ludecke G., Boman H., Sanchez-Carbayo M., Casella R., et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 173 5 (2005) 1518-1525
58. Grossman H.B., Messing E., Soloway M., Tomera K., Katz G., Berger Y., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 7 (2005) 810-816
59. Grossman H.B., Soloway M., Messing E., Katz G., Stein B., Kassabian V., et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295 3 (2006) 299-305
60. Lotan Y., and Shariat S.F. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int 101 11 (2008) 1362-1367
61. Lotan Y., Capitanio U., Shariat S.F., Hutterer G.C., and Karakiewicz P.I. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 103 10 (2009) 1368-1374
62. Junker K., Boerner D., Schulze W., Utting M., Schubert J., and Werner W. Analysis of genetic alterations in normal bladder urothelium. Urology 62 6 (2003) 1134-1138
63. Halling K.C. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 3 4 (2003) 507-519
64. Skacel M., Fahmy M., Brainard J.A., Pettay J.D., Biscotti C.V., Liou L.S., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169 6 (2003) 2101-2105
65. Friedrich M.G., Hellstern A., Toma M.I., Hammerer P., and Huland H. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence?. Eur Urol 43 2 (2003) 146-150 discussion 150-1
66. Halling K.C., King W., Sokolova I.A., Karnes R.J., Meyer R.G., Powell E.L., et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 167 5 (2002) 2001-2006
67. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 26 6 (2008) 646-651
68. Daniely M., Rona R., Kaplan T., Olsfanger S., Elboim L., Freiberger A., et al. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer 111 6 (2007) 517-524
69. Daniely M., Rona R., Kaplan T., Olsfanger S., Elboim L., Zilberstien Y., et al. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urology 66 6 (2005) 1354-1359
70. Lotan Y., Bensalah K., Ruddell T., Shariat S.F., Sagalowsky A.I., and Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 179 6 (2008) 2164-2169
71. Bergman J., Reznichek R.C., and Rajfer J. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. BJU Int 101 1 (2008) 26-29
72. Gofrit O.N., Zorn K.C., Silvestre J., Shalhav A.L., Zagaja G.P., Msezane L.P., et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 26 3 (2008) 246-249
73. Yoder B.J., Skacel M., Hedgepeth R., Babineau D., Ulchaker J.C., Liou L.S., et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 127 2 (2007) 295-301
74. Heicappell R., Schostack M., Müller M., and Miller K. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder. Scand J Clin Lab Invest 60 4 (2000) 275-282
75. Mian C., Lodde M., Haitel A., Egarter Vigl E., Marberger M., and Pycha A. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 56 2 (2000) 228-231
76. Saad A., Hanbury D.C., McNicholas T.A., Boustead G.B., and Woodman A.C. The early detection and diagnosis of bladder cancer: a critical review of the options. Eur Urol 39 (2001) 619-633
77. Babjuk M., Kostirova M., Mudra K., Pecher S., Smolova H., Pecen L., et al. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol 41 1 (2002) 34-39
78. Hakenberg O.W., Fuessel S., Richter K., Froehner M., Oehlschlaeger S., Rathert P., et al. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology 64 6 (2004) 1121-1126
79. Myers-Irvin J.M., Landsittel D., and Getzenberg R.H. Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol 174 1 (2005) 64-68
80. Konety B.R., Nguyen T.S., Dhir R., Day R.S., Becich M.J., Stadler W.M., et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 6 7 (2000) 2618-2625
81. Van Le T.S., Myers J., Konety B.R., Barder T., and Getzenberg R.H. Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res 10 4 (2004) 1384-1391
82. Van Le T.S., Miller R., Barder T., Babjuk M., Potter D.M., and Getzenberg R.H. Highly specific urine-based marker of bladder cancer. Urology 66 6 (2005) 1256-1260
83. Konety B.R., Nguyen T.S., Brenes G., Sholder A., Lewis N., Bastacky S., et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 164 3 Pt 1 (2000) 634-639
84. Knudson W. Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am J Pathol 148 6 (1996) 1721-1726
85. Lokeshwar V.B., Obek C., Soloway M.S., and Block N.L. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 57 4 (1997) 773-777
86. Lokeshwar V.B., and Block N.L. HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am 27 1 (2000) 53-61
87. Pham H.T., Block N.L., and Lokeshwar V.B. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 57 4 (1997) 778-783
88. Hautmann S.H., Lokeshwar V.B., Schroeder G.L., Civantos F., Duncan R.C., Gnann R., et al. Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. J Urol 165 6 Pt 1 (2001) 2068-2074
89. Lokeshwar V.B., Schroeder G.L., Selzer M.G., Hautmann S.H., Posey J.T., Duncan R.C., et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 95 1 (2002) 61-72
90. Hautmann S., Toma M., Lorenzo Gomez M.F., Friedrich M.G., Jaekel T., Michl U., et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol 46 4 (2004) 466-471
91. Decenzo J.M., Howard P., and Irish C.E. Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma. J Urol 114 6 (1975) 874-878
92. Golijanin D., Sherman Y., Shapiro A., and Pode D. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 46 2 (1995) 173-177
93. Pode D., Golijanin D., Sherman Y., Lebensart P., and Shapiro A. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 159 2 (1998) 389-392 discussion 393
94. Friedrich M.G., Hellstern A., Hautmann S.H., Graefen M., Conrad S., Huland E., et al. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests. J Urol 168 2 (2002) 470-474
95. van Rhijn B.W., Lurkin I., Kirkels W.J., van der Kwast T.H., and Zwarthoff E.C. Microsatellite analysis - DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 92 4 (2001) 768-775
96. Czerniak B., Chaturvedi V., Li L., Hodges S., Johnston D., Roy J.Y., et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18 5 (1999) 1185-1196
97. Knowles M.A., Elder P.A., Williamson M., Cairns J.P., Shaw M.E., and Law M.G. Allelotype of human bladder cancer. Cancer Res 54 2 (1994) 531-538
98. von Knobloch R., Hegele A., Brandt H., Olbert P., Heidenreich A., and Hofmann R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 94 1 (2001) 67-72
99. van der Aa M.N., Zwarthoff E.C., Steyerberg E.W., Boogaard M.W., Nijsen Y., van der Keur K.A., et al. Microsatellite analysis of voided-urine samples for surveillence of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). Eur Urol 55 3 (2009) 659-668
100. van der Poel H.G., van Balken M.R., Schamhart D.H., Peelen P., de Reijke T., Debruyne F.M., et al. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology 51 1 (1998) 44-50
101. Gregoire M., Fradet Y., Meyer F., Tetu B., Bois R., Bedard G., et al. Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. J Urol 157 5 (1997) 1660-1664
102. Cajulis R.S., Haines III G.K., Frias-Hidvegi D., McVary K., and Bacus J.W. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn Cytopathol 13 3 (1995) 214-223 discussion 224
103. Witjes J.A., van der Poel H.G., van Balken M.R., Debruyne F.M., and Schalken J.A. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 33 4 (1998) 387-391
104. Moonen P.M., Merkx G.F., Peelen P., Karthaus H.F., Smeets D.F., and Witjes J.A. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 51 5 (2007) 1275-1280 discussion 1280
105. Svatek R.S., Herman M.P., Lotan Y., Casella R., Hsieh J.T., Sagalowsky A.I., et al. Soluble Fas - a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 106 8 (2006) 1701-1707
106. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22 53 (2003) 8581-8589
107. Margulis V., Lotan Y., and Shariat S.F. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 26 1 (2008) 59-65
108. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., and Alterieri D.C. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285 3 (2001) 324-328
109. Shariat S.F., Casella R., Khoddami S.M., Hernandez G., Sulser T., Gasser T.C., et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171 2 Pt 1 (2004) 626-630
110. Schultz I.J., Kiemeney L.A., Karthaus H.F., Witjes J.A., Willems J.L., Swinkels D.W., et al. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 50 8 (2004) 1425-1428
111. Weikert S., Christoph F., Schrader M., Krause H., Miller K., and Müller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116 1 (2005) 100-104
112. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., and Altieri D.C. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285 3 (2001) 324-328
113. Greider C.W. Telomere length regulation. Annu Rev Biochem 65 (1996) 337-365
114. Blackburn E.H. Telomeres and their synthesis. Science 249 (1990) 489-490
115. Blackburn E.H. Structure and function of telomeres. Nature 350 (1991) 569-573
116. Morin G.B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59 (1989) 521-529
117. Ito H., Kyo S., Kanaya T., Takakura M., Inoue M., and Namiki M. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res 4 7 (1998) 1603-1608
118. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
119. De Kok J.B., Schalken J.A., Aalders T.W., Ruers T.J., Willems H.L., and Swinkels D.W. Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. Int J Cancer 87 2 (2000) 217-220
120. Melissourgos N., Kastrinakis N.G., Davilas I., Foukas P., Farmakis A., and Lykourinas M. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology 62 2 (2003) 362-367
121. Wu X., Kakehi Y., Takahashi T., Habuchi T., and Ogawa O. Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence. Int J Urol 7 (2000) 210-217
122. Cheng C.W., Chueh S.C., and Chern H.D. Diagnosis of bladder cancer using telomerase activity in voided urine. J Formos Med Assoc 99 12 (2000) 920-925
123. Cassel A., Rahat M.A., Lahat N., Lindenfield N., Mecz Y., and Stein A. Telomerase activity and cytokeratin 20 as markers for the detection and followup of transitional cell carcinoma: an unfulfilled promise. J Urol 166 (2001) 841-844
124. Kavaler E., Landman J., Chang Y., Droller M.J., and Liu B.C. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 82 4 (1998) 708-714
125. Lee D.H., Yang S.C., Hong S.J., Chung B.H., and Kim I.Y. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res 4 3 (1998) 535-538
126. Dalbagni G., Han W., Zhang Z.F., Cordon-Cardo C., Saigo P., Fair W.R., et al. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. Clin Cancer Res 3 9 (1997) 1593-1598
127. Yokota K., Kanda K., Inoue Y., Kanayama H., and Kagawa S. Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma. Br J Urol 82 5 (1998) 727-732
128. Mayfield M.P., Shah T., Flannigan G.M., Hamilton Stewart P.A., and Bibby M.C. Telomerase activity in malignant and benign bladder conditions. Int J Mol Med 1 5 (1998) 835-840
129. Müller M., Krause H., Heicappell R., Tischendorf J., Shay J.W., and Miller K. Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res 4 8 (1998) 1949-1954
130. Lee M.Y., Tsou M.H., Cheng M.H., Chang D.S., Yang A.L., and Ko J.S. Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma. World J Urol 18 (2000) 401-405
131. Weikert S., Krause H., Wolff I., Christoph F., Schrader M., Emrich T., et al. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer 117 2 (2005) 274-280
132. Sanchini M.A., Gunelli R., Nanni O., Bravaccini S., Fabbri C., Sermasi A., et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 294 16 (2005) 2052-2056
133. Guo B., Luo C., Xun C., Xie J., Wu X., and Pu J. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR. Exp Oncol 31 1 (2009) 43-47
134. Soloway M.S. Bladder tumor markers, intravesical therapy and systemic chemotherapy (Editorial). J Urol 166 (2001) 488-489
135. Yossepowitch O., Herr H.W., and Donat S.M. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol 177 4 (2007) 1277-1282 discussion 1282
136. Bensalah K., Montorsi F., and Shariat S.F. Challenges of cancer biomarker profiling. Eur Urol 52 6 (2007) 1601-1609